1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Bupropion / Naltrexone |
| brand | String | Contrave (US), Mysimba (EU) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Antidepressants|Antidepressant (bupropion • atypical)]] • [[:Category:Opioid_antagonists|Opioid antagonist (naltrexone)]] • [[:Category:Anorectics|Anorectic (weight-loss agent)]] • [[:Category:Fixed-dose_combinations|Fixed-dose combination]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00001567-QINU`"' |
| starting_dose | String | Week 1: 1 tablet (8/90 mg) PO morning; week 2: 1 tablet AM + 1 PM; week 3: 2 AM + 1 PM; week 4 onward: 2 AM + 2 PM (32 mg naltrexone / 360 mg bupropion/d) |
| preparations | String | 8 mg naltrexone / 90 mg bupropion ER tablets (titration-pack design) |
| fda_max | String | 32 mg naltrexone / 360 mg bupropion per day |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Modest appetite suppression within weeks; weight loss over months |
| duration | String | 12 hours (BID dosing required) |
| halflife | String | Naltrexone ~4 hours (6β-naltrexol metabolite ~13 hours); bupropion ~21 hours'"`UNIQ--ref-00001568-QINU`"' |
| bioavailability | String | Naltrexone ~5% (oral, extensive first-pass to 6β-naltrexol); bupropion ER ~87%'"`UNIQ--ref-00001569-QINU`"' |
| pregnancy | String | Contraindicated in pregnancy (FDA label).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | |
